Revaccination of Young Children With Bacille Calmette Guerin (BCG) Vaccine

NCT ID: NCT00126217

Last Updated: 2008-10-21

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE4
• Total Enrollment: 2871 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2002-07-31
• Study Completion Date: 2006-09-30

Brief Summary

BCG has marked immune stimulatory effects in both animal and human studies and observational studies suggest that BCG is associated with a non-specific reduction in mortality in areas with high infant and child mortality. The specific objective of the study is to examine the effect of revaccination for purified protein derivative of tuberculin (PPD) reaction, scar size, morbidity and mortality in a randomised prospective study of revaccination versus no revaccination among children 19 months of age in Guinea-Bissau. The hypothesis is that revaccination with BCG reduces childhood mortality after 19 months of age by 30%.

Detailed Description

Examine in a randomised trial whether revaccination with BCG reduces childhood mortality after 19 months of age by 30%.

Criteria for verification: 3,000 children aged 1½ year enrolled and followed for an average of 3 years; information on potential adverse events among children with a positive PPD reaction; assessment of parasitaemia after revaccination; assessment of the tuberculin response and scar-formation after revaccination; and assessment of all-cause mortality during the period of follow-up.

Following consent to participate, children will be assessed for BCG scar and tuberculin reaction at 18-19 months of age. Subsequently, the children will be invited to a clinical examination at one of the health centres. The study will be explained again to the mother, and if she accepts to participate, she will draw a randomisation number deciding whether the child will be revaccinated or not. The BCG vaccine given will be the standard dose of 0.1 ml as recommended by WHO in this age group. In the beginning of the study, a group of 800 revaccinated and not revaccinated children will be followed weekly for two months to monitor morbidity and possible adverse effects of the vaccination. It is not expected that Koch like reactions will be common in this age group. However, should there be too many adverse reactions among children with a positive tuberculin test, only tuberculin negative children will be included in the continuation of the trial.

Two months after inclusion, the children will have another tuberculin test to examine changes in tuberculin reaction. At the same time, scar-size will be measured. In the initial phase of the project, a finger-prick blood sample will be collected from 1000 children to examine whether BCG boosting/no boosting have had an effect on the prevalence of malaria parasitaemia and the level of measles antibodies. Children with malaria will be treated and children with non-protective levels of measles antibodies will be offered revaccination with measles vaccine. In a group of children, samples will be collected both before and after BCG revaccination/no revaccination to measure changes in cytokine profile. Children with a large PPD reaction (> 15mm) will be followed in a similar way as the other children as this may reflect immune stimulation from exposure to natural TB. The studies of morbidity and immunological changes will be done both in the dry and the rainy seasons. The children will be followed for hospitalisations and mortality to 5 years of age.

Conditions

Malaria

Keywords

Non-specific effects of vaccines; Infant mortality; Morbidity; Low income country; Malaria; BCG; immunisation; BCG revaccination; Tuberculin; Mortality

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

1

Group Type: EXPERIMENTAL

Bacille Calmette Guerin (BCG)

Intervention Type: BIOLOGICAL

0,1 ml, revaccination at 19 months of age

2

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Bacille Calmette Guerin (BCG)

0,1 ml, revaccination at 19 months of age

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• No overt illness

Exclusion Criteria

• PPD reaction >15mm

• Minimum Eligible Age: 19 Months
• Maximum Eligible Age: 24 Months
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

International Cooperation with Developing Countries

OTHER

Sponsor Role: collaborator

Leiden University Medical Centre, DEPT of Parasitology, Leiden Holland

OTHER

Sponsor Role: collaborator

Medical Research Council Unit, The Gambia

OTHER

Sponsor Role: collaborator

Bandim Health Project

OTHER

Sponsor Role: lead

Responsible Party

Apartado 861, Bissau,Guinea-Bissau

Principal Investigators

Peter Aaby

Role: PRINCIPAL_INVESTIGATOR

Bandim Health Project

Locations

Bandim Health Project

Apartado 861, Bissau, , Guinea-Bissau

Countries

Guinea-Bissau

Other Identifiers

EU contract ICA4-CT-2002-10053

Identifier Type: -

Identifier Source: secondary_id

ICA4-CT-2002-10053-REVAC

Identifier Type: -

Identifier Source: org_study_id